JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on August 1, 2007; DOI: 10.1124/jpet.107.127068


0022-3565/07/3232-570-578$20.00
JPET 323:570-578, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.107.127068v1
323/2/570    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, X.
Right arrow Articles by Ding, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, X.
Right arrow Articles by Ding, X.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*8-METHOXYPSORALEN

METABOLISM, TRANSPORT, AND PHARMACOGENOMICS

CYP2A13: Variable Expression and Role in Human Lung Microsomal Metabolic Activation of the Tobacco-Specific Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone

Xiuling Zhang, Jaime D'Agostino, Hong Wu, Qing-Yu Zhang, Linda von Weymarn, Sharon E. Murphy, and Xinxin Ding

Wadsworth Center, New York State Department of Health, and School of Public Health, State University at New York, Albany, New York (X.Z., J.D., H.W., Q.-Y.Z., X.D.); and University of Minnesota Cancer Center, University of Minnesota, Minneapolis, Minnesota (L.v.W., S.E.M.)

CYP2A13 is the most efficient cytochrome P450 enzyme in the metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific lung carcinogen. The aims of this study were to determine the levels of CYP2A13 protein in human lung microsomes and to ascertain whether CYP2A13 plays any role in lung microsomal NNK metabolic activation. The expression of CYP2A6 and CYP2A13 was examined using a high-resolution immunoblotting method, following immunopurification with an anti-CYP2A5 antibody. We found that, of 116 human lung microsomal samples analyzed, ~90% had detectable CYP2A6, whereas only 12% had detectable CYP2A13 with a detection limit of ~2 fmol of CYP2A/mg protein. For the majority of microsomal samples analyzed, the level of CYP2A13 was found to be lower than the level of CYP2A6; overall, the highest level of CYP2A13 found (~20 fmol/mg protein) was ~10-fold lower than the highest level of CYP2A6 detected. Quantitative RNA-polymerase chain reaction analysis confirmed that the highly variable expression of the CYP2A proteins was consistent with variations in the levels of the corresponding CYP2A mRNAs in the same tissue samples. It is noteworthy that the level of CYP2A13, but not CYP2A6, was correlated with lung microsomal NNK metabolic activation activity. Furthermore, the addition of 8-methoxypsoralen, a CYP2A inhibitor, led to greater inhibition of NNK metabolic activation in microsomes containing relatively high levels of CYP2A13 than in samples containing no detectable CYP2A13. Taken together, these data indicate that human lung microsomal CYP2A13 is active in NNK metabolic activation. Therefore, individuals having relatively high levels of CYP2A13 expression will likely have an increased risk of developing smoking-related lung cancer.


Received for publication June 11, 2007
Accepted July 30, 2007.

Address correspondence to: Dr. Xinxin Ding, Wadsworth Center, New York State Department of Health, Empire State Plaza, Box 509, Albany, NY 12201-0509. E-mail: xding{at}wadsworth.org




This article has been cited by other articles:


Home page
Cancer Res.Home page
Y. Y. Kim, L. Von Weymarn, O. Larsson, D. Fan, J. M. Underwood, M. S. Peterson, S. S. Hecht, V. A. Polunovsky, and P. B. Bitterman
Eukaryotic Initiation Factor 4E Binding Protein Family of Proteins: Sentinels at a Translational Control Checkpoint in Lung Tumor Defense
Cancer Res., November 1, 2009; 69(21): 8455 - 8462.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
J. D'Agostino, X. Zhuo, M. Shadid, D. G. Morgan, X. Zhang, W. G. Humphreys, Y.-Z. Shu, G. S. Yost, and X. Ding
The Pneumotoxin 3-Methylindole Is a Substrate and a Mechanism-Based Inactivator of CYP2A13, a Human Cytochrome P450 Enzyme Preferentially Expressed in the Respiratory Tract
Drug Metab. Dispos., October 1, 2009; 37(10): 2018 - 2027.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
J. D'Agostino, X. Zhang, H. Wu, G. Ling, S. Wang, Q.-Y. Zhang, F. Liu, and X. Ding
Characterization of CYP2A13*2, a Variant Cytochrome P450 Allele Previously Found to Be Associated with Decreased Incidences of Lung Adenocarcinoma in Smokers
Drug Metab. Dispos., November 1, 2008; 36(11): 2316 - 2323.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.